Sunitinib Malate Market Report

Market Insights

What is sunitinib malate?

Sunitinib malate is known as the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor. Based on purity, sunitinib malate can be categorized as >99%, >98%, and >97%. It is a small-molecule inhibitor of multiple receptor tyrosine kinases involved in cancer.

The Sunitinib Malate market is projected to grow from USD xx billion in 2020 to USD xx billion by 2026 at a CAGR of around x% during the forecast period.

Figure: Sunitinib Malate Market Size, 2020-2026 (USD Billion)

Wish to get a free sample? Register Here

Market Drivers

The growth of the sunitinib malate market is driven by the increasing prevalence of the gastrointestinal disorder. Expanding geriatric populace coupled with rising cases of pancreatic cancer is expected to drive the market growth at a significant rate. In addition to this, increasing investment in R&D activities for new drug development is likely to create lucrative opportunities for the players operating in the global market during the review period.

COVID-19 Impact on Sunitinib Malate Market

The covid-19 outbreak posed significant challenges across verticals worldwide. Supply chain disruptions due to the imposition of lockdown affected the product availability on time and thus, affected the market growth.

Segments' Analysis

Application Trends

Based on application, the market has been segmented into pancreatic neuroendocrine tumors, kidney cancer, and gastrointestinal stromal tumor. Among these, the pancreatic neuroendocrine tumors segment accounted for the largest market share in 2020 and is expected to propel market growth at a significant rate during the review period. The segment growth can be attributed to the increasing number of people suffering from pancreatic cancer disease.

Regional Trends

The market in the North American region accounted for the largest market share in 2020 and is expected to grow at a healthy CAGR during the review period. The regional market growth can be attributed to the prevalence of a large number of people suffering from chronic kidney diseases and the presence of key market players such as Pfizer Inc. (US) and Top Care Pharmacy (US). The market in Asia-Pacific is expected to register significant growth on account of increasing incidences of gastrointestinal disorders, particularly in developing countries.

Critical Questions Answered in the Report

This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Sunitinib Malate market. The historic years considered for the study are 2016-2019, the base year is 2020, and the forecast period is 2021-2026. Following are the critical questions answered in the report-

• What are the key trends in the Sunitinib Malate market?
• How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
• What is the impact of COVID-19 on the Sunitinib Malate market?
• What are the key strategies adopted by the major vendors to lead in the Sunitinib Malate market?
• What is the market share of the top vendors?

Get the full scope of the report. Register Here

Key Players

Key players operating in the Sunitinib Malate market are-

• Pfizer Inc. (US)
• Top Care Pharmacy (US)
• J&K Scientific (China)
• Targetmol (US)
• Active Biotech AB (Sweden)
• Astellas Pharma Inc. (Japan)
• AstraZeneca plc (UK)
• Bristol Myers Squibb (US)
• Dendreon (US)
• Endo International plc (Ireland)
• Ferring Pharmaceuticals Inc. (US).

Target Audience

Here is the list of the group of customers that the sunitinib malate market hopes to have the greatest opportunity to convert-

• Sunitinib malate distributors
• Sunitinib malate suppliers
• Sunitinib malate manufacturers
• Logistics organizations
• Government bodies

Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.